Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy ...

Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...

Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply ...

Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection pens for CagriSema, the former’s ...

This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong, with no signs of business deterioration. Despite Eli Lilly's underperformance in GLP-1 sales ...

2024 Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The firm’s analysis suggests CagriSema is likely to deliver 25% ...

Novo Nordisk (NVO) said for the 2024 outlook, sales growth is now expected to be 23-27% at CER, and operating profit growth is now expected to be 21-27% at CER. Growth reported in Danish kroner is ...